Expanded SEER Registries Dataset Shows Improved Survival for DecisionDx-Melanoma Tested Patients Compared to Untested Patients

In a recent study, patients diagnosed with melanoma and tested with DecisionDx-Melanoma had improved survival (27% improvement in melanoma-specific survival) compared to untested patients.

Related Keywords

Spain ,Derek Maetzold ,Castle Biosciences ,Camilla Zuckero ,Decisiondx Diffdx ,Texas Castle Biosciences Inc ,Linkedin ,National Cancer Institute ,European Association Of Dermato Oncology ,Castle Biosciences Inc ,Securities Exchange ,Nasdaq ,End Results ,European Association ,Dermato Oncology ,Decisiondx Melanoma Class ,About Decisiondx ,Integrated Test ,Path Melanoma ,Decisiondx Diffdx Melanoma ,Securities Act ,Securities Exchange Act ,Annual Report ,Diagnostics ,